Skip to Content
Merck

A7655

Atenolol

≥98% (TLC), powder, β₁-adrenoceptor antagonist

Atenolol

Synonym(s):

(±)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide, 4-[2′-Hydroxy-3′-(isopropylamino)propoxy]phenylacetamide

Slide 1 of 1
Sign In to View Organizational & Contract Pricing.

Select a Size

Pricing and availability is not currently available.

About This Item

Empirical Formula (Hill Notation):
C14H22N2O3
CAS Number:
29122-68-7
Molecular Weight:
266.34
NACRES:
NA.77
PubChem Substance ID:
24277748
UNSPSC Code:
12352200
EC Number:
249-451-7
MDL number:
MFCD00057645
Assay:
≥98% (TLC)
Form:
powder
Quality level:
200

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Atenolol, ≥98% (TLC), powder

InChI key

METKIMKYRPQLGS-UHFFFAOYSA-N

InChI

1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)

SMILES string

CC(C)NCC(O)COc1ccc(CC(N)=O)cc1

assay

≥98% (TLC)

form

powder

color

white to off-white

solubility

H2O: 0.3 mg/mL, DMSO: 18 mg/mL, ethanol: 3.4 mg/mL

originator

AstraZeneca

Quality Level

200

Gene Information

human ... ADRB1(153)
rat ... Adrb1(24925)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
PHR19091044403A-072
Atenolol ≥98% (TLC), powder

Sigma-Aldrich

A7655

Atenolol

Atenolol Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1909

Atenolol

Atenolol United States Pharmacopeia (USP) Reference Standard

USP

1044403

Atenolol

Atenolol solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

A-072

Atenolol solution

assay

≥98% (TLC)

assay

-

assay

-

assay

-

form

powder

form

powder

form

-

form

liquid

Quality Level

200

Quality Level

300

Quality Level

-

Quality Level

300

solubility

H2O: 0.3 mg/mL, ethanol: 3.4 mg/mL, DMSO: 18 mg/mL

solubility

-

solubility

-

solubility

-

color

white to off-white

color

-

color

-

color

-

originator

AstraZeneca

originator

-

originator

-

originator

-

Application

Atenolol is a β-adrenergic blocker and used in the management of hypertension. Atenolol has antianginal and antiarrhythmic properties.

Biochem/physiol Actions

Selective β1-adrenoceptor antagonist; antihypertensive; antianginal; antiarrhythmic.

Features and Benefits

This compound is featured on the β-Adrenoceptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Shelf-life of the solid is at least three years.

related product

Product No.
Description
Pricing

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
BCCP1635
BCCL7859
BCCK4552
BCCG8517
BCCD4543

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ganesha Rai et al.
Journal of medicinal chemistry, 52(20), 6474-6483 (2009-09-19)
Schistosomiasis is a chronic parasitic disease affecting hundreds of millions of individuals worldwide. Current treatment depends on a single agent, praziquantel, raising concerns of emergence of resistant parasites. Here, we continue our explorations of an oxadiazole-2-oxide class of compounds we
Hsin-Hui Chiu et al.
Mayo Clinic proceedings, 88(3), 271-276 (2013-01-17)
To assess the tolerability and efficacy of the investigational use of the angiotensin II receptor blocker losartan added to β-blockade (BB) to prevent progressive aortic root dilation in patients with Marfan syndrome (MFS). Between May 1, 2007, and September 31
Ronald V Lacro et al.
American heart journal, 165(5), 828-835 (2013-04-30)
The Pediatric Heart Network designed a clinical trial to compare aortic root growth and other short-term cardiovascular outcomes in children and young adults with Marfan syndrome randomized to receive atenolol or losartan. We report here the characteristics of the screened
Tzu-Heng Huang et al.
International journal of molecular sciences, 22(21) (2021-11-14)
Thoracic aortic aneurysm (TAA) formation is a multifactorial process that results in diverse clinical manifestations and drug responses. Identifying the critical factors and their functions in Marfan syndrome (MFS) pathogenesis is important for exploring personalized medicine for MFS. Methylenetetrahydrofolate reductase
Ronald V Lacro et al.
The New England journal of medicine, 371(22), 2061-2071 (2014-11-19)
Aortic-root dissection is the leading cause of death in Marfan's syndrome. Studies suggest that with regard to slowing aortic-root enlargement, losartan may be more effective than beta-blockers, the current standard therapy in most centers. We conducted a randomized trial comparing
View All Related Papers
1 Review This action will navigate to reviews.

Questions

1 Review This action will navigate to reviews.

Reviews

Active Filters

  1. 1 Ratings-only review

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service